MIM
LAB icon

MetLife Investment Management’s Standard BioTools LAB Stock Holding History

MetLife Investment Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79.3K Sell
86,220
-38,668
-31% -$46.8K ﹤0.01% 2624
2025
Q4 		$160K Sell
124,888
-28,041
-18% -$37.7K ﹤0.01% 2386
2025
Q3 		$199K Sell
152,929
-28,333
-16% -$37.1K ﹤0.01% 2318
2025
Q2 		$218K Buy
181,262
+60,285
+50% +$66.8K ﹤0.01% 2145
2025
Q1 		$131K Sell
120,977
-62,405
-34% -$87.6K ﹤0.01% 2403
2024
Q4 		$321K Buy
183,382
+40,057
+28% +$74.6K ﹤0.01% 2033
2024
Q3 		$277K Buy
143,325
+66,410
+86% +$130K ﹤0.01% 2119
2024
Q2 		$136K Buy
+76,915
New +$188K ﹤0.01% 2455
2022
Q2 		– Sell
-35,462
Closed -$127K – 2887
2022
Q1 		$127K Buy
35,462
+26,153
+281% +$90.3K ﹤0.01% 2574
2021
Q4 		$36.5K Sell
9,309
-20,592
-69% -$96.4K ﹤0.01% 2474
2021
Q3 		$197K Hold
29,901
– – ﹤0.01% 2113
2021
Q2 		$184K Buy
29,901
+23,924
+400% +$128K ﹤0.01% 2220
2021
Q1 		$27K Sell
5,977
-26,759
-82% -$147K ﹤0.01% 2298
2020
Q4 		$196K Sell
32,736
-3,119
-9% -$20.5K ﹤0.01% 1995
2020
Q3 		$266K Hold
35,855
– – ﹤0.01% 1686
2020
Q2 		$144K Buy
+35,855
New +$125K ﹤0.01% 2075
2019
Q4 		– Sell
-32,475
Closed -$150K – 2317
2019
Q3 		$150K Hold
32,475
– – ﹤0.01% 2101
2019
Q2 		$400K Buy
32,475
+16,371
+102% +$209K ﹤0.01% 1614
2019
Q1 		$214K Buy
+16,104
New +$170K ﹤0.01% 1948
2018
Q2 		– Sell
-20,596
Closed -$120K – 2199
2018
Q1 		$120K Hold
20,596
– – ﹤0.01% 2128
2017
Q4 		$121K Buy
+20,596
New +$113K ﹤0.01% 2171

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

MetLife Investment Management's LAB Position: Q1 2026 in Review

MetLife Investment Management reduced its Standard BioTools (LAB) stake by 31% in Q1 2026, selling an estimated $46.8K and leaving 86,220 shares worth $79.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2624.

MetLife Investment Management first reported a position in LAB in Q4 2017 and has held it in 21 quarters since. The position peaked at $400K in Q2 2019. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • MetLife Investment Management held 86,220 shares of Standard BioTools worth $79.3K as of Q1 2026.
  • MetLife Investment Management sold 38,668 Standard BioTools shares in Q1 2026, an estimated $46.8K.
  • Standard BioTools made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2624 holding.
  • MetLife Investment Management first reported a position in Standard BioTools in Q4 2017 and has held it in 21 quarters since.
  • MetLife Investment Management's Standard BioTools position peaked at $400K in Q2 2019.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.